155 related articles for article (PubMed ID: 11204561)
1. Antithrombotic efficacy in a rat model of the low molecular weight heparin, reviparin sodium, administered by the oral route.
Hiebert LM; Wice SM; Ping T; Herr D; Laux V
Thromb Haemost; 2001 Jan; 85(1):114-8. PubMed ID: 11204561
[TBL] [Abstract][Full Text] [Related]
2. Absorption and antithrombotic activity of unfractioned heparin after intraduodenal administration in rats.
Costantini V; Deveglia R; Stabile A; Nenci GG
Blood Coagul Fibrinolysis; 2000 Jan; 11(1):7-13. PubMed ID: 10691095
[TBL] [Abstract][Full Text] [Related]
3. Tissue distribution and antithrombotic activity of unlabeled or 14C-labeled porcine intestinal mucosal heparin following administration to rats by the oral route.
Hiebert LM; Wice SM; Ping T; Hileman RE; Capila I; Linhardt RJ
Can J Physiol Pharmacol; 2000 Apr; 78(4):307-20. PubMed ID: 10772058
[TBL] [Abstract][Full Text] [Related]
4. Oral heparins.
Hiebert LM
Clin Lab; 2002; 48(3-4):111-6. PubMed ID: 11934211
[TBL] [Abstract][Full Text] [Related]
5. Orally administered heparins prevent arterial thrombosis in a rat model.
Pinel C; Wice SM; Hiebert LM
Thromb Haemost; 2004 May; 91(5):919-26. PubMed ID: 15116252
[TBL] [Abstract][Full Text] [Related]
6. Antithrombotic activity of orally administered low molecular weight heparin (Logiparin) in a rat model.
Hiebert LM; Ping T; Wice SM
Haemostasis; 2000; 30(4):196-203. PubMed ID: 11155038
[TBL] [Abstract][Full Text] [Related]
7. Additive effect of the combined administration of low molecular weight heparin and recombinant hirudin on thrombus growth in a rabbit jugular vein thrombosis model.
Biemond BJ; Levi M; Nurmohamed MT; Büller HR; ten Cate JW
Thromb Haemost; 1994 Sep; 72(3):377-80. PubMed ID: 7855787
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological profile of reviparin-sodium.
Hoppensteadt D; Jeske W; Fareed J
Blood Coagul Fibrinolysis; 1993 Dec; 4 Suppl 1():S11-6. PubMed ID: 8180323
[TBL] [Abstract][Full Text] [Related]
9. Repeated Oral or Subcutaneous LMWH Has similar Antithrombotic Activity in a Rat Venous Thrombosis Model: Antithrombotic Activity Correlates With Heparin on Endothelium When Orally Administered.
Hiebert LM
J Cardiovasc Pharmacol Ther; 2017 May; 22(3):264-272. PubMed ID: 27653610
[TBL] [Abstract][Full Text] [Related]
10. Tissue distribution of the low molecular weight heparin, tinzaparin, following administration to rats by the oral route.
Hiebert LM; Wice SM; Ping T
Biomed Pharmacother; 2004; 58(6-7):372-80. PubMed ID: 15271419
[TBL] [Abstract][Full Text] [Related]
11. Antithrombotic and thrombolytic activity of heparins in a rat model of laser-induced thrombosis.
Krupiński K; Giedrojć J; Breddin HK; Bielawiec M
Pol J Pharmacol; 1996; 48(3):345-50. PubMed ID: 9112675
[TBL] [Abstract][Full Text] [Related]
12. Fucosylated chondroitin sulfate as a new oral antithrombotic agent.
Fonseca RJ; Mourão PA
Thromb Haemost; 2006 Dec; 96(6):822-9. PubMed ID: 17139379
[TBL] [Abstract][Full Text] [Related]
13. Potent arterial antithrombotic effect of direct factor-Xa inhibition with ZK-807834 administered to coronary artery disease patients.
Zafar MU; Farkouh ME; Osende J; Shimbo D; Palencia S; Crook J; Leadley R; Fuster V; Chesebro JH
Thromb Haemost; 2007 Mar; 97(3):487-92. PubMed ID: 17334518
[TBL] [Abstract][Full Text] [Related]
14. Evidence for the absorption of heparin by rat stomach.
Hiebert LM; Wice SM; Abdelhameed T
Biomed Pharmacother; 2007 Jan; 61(1):68-74. PubMed ID: 17196786
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic validation of the clinical effects of an optimized low-molecular-weight heparin-reviparin.
Fareed J; Jeske W; Eschenfelder V; Iqbal O; Hoppensteadt D; Ahsan A
Semin Thromb Hemost; 1995; 21(2):212-27. PubMed ID: 7660144
[TBL] [Abstract][Full Text] [Related]
16. A comparative study of the anticoagulant and anti-thrombotic effects of unfractionated heparin and a low molecular weight heparin (Fraxiparine) in an experimental model of human venous thrombosis.
Diquélou A; Dupouy D; Cariou R; Sakariassen KS; Boneu B; Cadroy Y
Thromb Haemost; 1995 Nov; 74(5):1286-92. PubMed ID: 8607111
[TBL] [Abstract][Full Text] [Related]
17. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
Melo FR; Mourão PA
Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
[TBL] [Abstract][Full Text] [Related]
18. A newly developed oral heparin derivative for deep vein thrombosis: non-human primate study.
Kim SK; Lee DY; Kim CY; Nam JH; Moon HT; Byun Y
J Control Release; 2007 Nov; 123(2):155-63. PubMed ID: 17884230
[TBL] [Abstract][Full Text] [Related]
19. Interaction between the sulfated lactobionic acid (LW 10082) and other antithrombotic agents in animal thrombosis model.
Giedrojć J; Krupiński K; Breddin HK; Bielawiec M
Pol J Pharmacol; 1996; 48(3):317-22. PubMed ID: 9112669
[TBL] [Abstract][Full Text] [Related]
20. Antithrombotic potential of GW813893: a novel, orally active, active-site directed factor Xa inhibitor.
Abboud MA; Needle SJ; Burns-Kurtis CL; Valocik RE; Koster PF; Amour AJ; Chan C; Brown D; Chaudry L; Zhou P; Patikis A; Patel C; Pateman AJ; Young RJ; Watson NS; Toomey JR
J Cardiovasc Pharmacol; 2008 Jul; 52(1):66-71. PubMed ID: 18645410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
